XTX Topco Ltd Takes Position in Dynavax Technologies Co. (NASDAQ:DVAX)

XTX Topco Ltd purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 16,357 shares of the biopharmaceutical company’s stock, valued at approximately $184,000.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Dynavax Technologies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after acquiring an additional 126,458 shares in the last quarter. Kynam Capital Management LP increased its holdings in shares of Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after purchasing an additional 2,725,397 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Dynavax Technologies by 21.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock valued at $50,288,000 after purchasing an additional 644,428 shares during the period. Renaissance Technologies LLC boosted its holdings in Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after buying an additional 53,600 shares in the last quarter. Finally, Mizuho Markets Americas LLC grew its position in Dynavax Technologies by 37.9% during the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after buying an additional 323,050 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Dynavax Technologies Stock Up 1.3 %

Shares of NASDAQ DVAX opened at $11.14 on Tuesday. The firm’s 50-day moving average is $11.08 and its two-hundred day moving average is $11.40. The company has a market capitalization of $1.46 billion, a PE ratio of 187.17 and a beta of 1.37. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $15.15. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The firm had revenue of $73.80 million for the quarter, compared to analysts’ expectations of $76.92 million. During the same quarter in the prior year, the firm earned $0.03 EPS. Equities analysts anticipate that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.